Mode
Text Size
Log in / Sign up
Phase 4 N=366 Diagnostic

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

Coronary Artery Disease · Heart Disease

Enrolled (actual)
366
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcome: Primary: Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up — 2; 1; 1; 5 Participants — p=0.014

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Perflutren Lipid Microsphere Injectable Suspension (Drug)
Age
Adult, Older Adult · 40+ yrs
Sex
Female
Sponsor
Lantheus Medical Imaging
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up
2; 1; 1; 5 0.014 sig
SECONDARY
Number of Participants With Abnormal ECG and With Major Adverse Cardiac Events (MACE) at 2 Year Follow-Up
3; 15 <0.0001 sig
SECONDARY
Change in Brain Natriuretic Peptide (BNP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.
5.2; 10.7
SECONDARY
Change in Atrial Natriuretic Peptide (ANP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.
5.9; 101
SECONDARY
Change in Brachial Artery Reactivity Was Assessed in in a Subset of Participants With and Without Major Adverse Cardiac Events at 2-year and 5-year Follow-up.
7.8; 7.3
SECONDARY
Mean Baseline Calcium Score of Participants With and Without Major Cardiac Events at 2-year Follow up.
45
SECONDARY
The Presence of Wall Motion Abnormalities on Definity Stress Echocardiography Assessed for Participants With Both Normal and Abnormal Angiography
7; 12; 1; 4
SECONDARY
Participants With Positive and Negative Angiography Compared With Their ECG Results
15; 4; 3; 2
SECONDARY
Number of Participants With Abnormal ECG and With Future Major Adverse Cardiac Events (MACE) at 5 Years Follow-Up
16.7; 5.0
SECONDARY
Change in Brain Natriuretic Peptide (BNP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.
4.9; 4.1
SECONDARY
Change in Atrial Natriuretic Peptide (ANP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.
-37.4; 70.5
SECONDARY
Mean Calcium Score of Participants With and Without Major Cardiac Events at 5-year Follow up.
40.2; 100

Summary

The study is designed to see if stress echocardiography can be used as a screening exam in peri-, or post-menopausal women with a risk of developing of coronary artery disease and experiencing future cardiac events.

Eligibility Criteria

Inclusion Criteria

  • Peri or Post menopausal women either:
  • without symptoms but with risk factors for heart disease OR
  • experiencing atypical chest pain, OR
  • experiencing exertional dyspnea AND 2 or more risk factors for CAD
  • Must be able to perform an exercise stress test

Peri-or post-menopausal (including surgical menopause) based on history.

  • Post-menopausal is defined as females age 40-65 who self-report the absence of menstrual periods for at least 12 months.
  • Peri-menopausal is defined as females age 40-65 who self-report the absence or irregularity of menstrual periods for 6-12 months.
  • Surgical menopause is defined as females who have had a bilateral salpingo-oophorectomy with or without hysterectomy.

Exclusion Criteria

  • Previous confirmed heart disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00162370). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search